Evaluating gene alterations in lung cancer using EBUS-TBNA samples
Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer
University Health Network, Toronto · NCT01487603
This study is testing if samples taken from lung cancer patients using a special needle procedure can help find genetic changes that might improve treatment options and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT01487603 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the feasibility of using samples obtained through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to analyze genetic alterations in patients with lung cancer. By focusing on patients with confirmed or suspected lung cancer who require EBUS-TBNA for staging, the study seeks to identify specific target molecules that correlate with treatment effectiveness and prognosis. The approach is particularly important for patients with advanced disease who are not candidates for surgery, as it allows for non-invasive specimen collection for molecular analysis. The findings could enhance personalized treatment strategies based on genetic profiles.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed or suspected lung cancer requiring EBUS-TBNA for staging.
Not a fit: Patients who are not medically fit for bronchoscopy or have a high suspicion of lymphoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment outcomes for lung cancer patients by enabling personalized therapy based on genetic analysis.
How similar studies have performed: Other studies have shown promise in using non-surgical methods for genetic analysis in lung cancer, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. * Patients with confirmed or suspected lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum will be considered for the trial. * Patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for lung cancer in which a tissue diagnosis is required. Exclusion Criteria: * Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy. * Patients where there is a high clinical suspicion of lymphoma.
Where this trial is running
Toronto, Ontario
- University Health Network — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Kazuhiro Yasufuku, MD — UHN
- Study coordinator: Judy McConnell
- Email: judy.mcconnell@uhn.ca
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Patients, undiagnosed enlarged, lymph nodes